| [1] |
Arber DA,Orazi A,Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
|
| [2] |
浦权. 骨髓增生异常综合征诊断与分型的新认识[J]. 中华内科杂志, 1999, 38(6): 365-367.
|
| [3] |
Matsushima T,Handa H,Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia[J]. Blood, 2003, 101(9): 3386-3390.
|
| [4] |
Wimazal F,Germing U,Kundi M, et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes[J]. Cancer, 2010, 116(10): 2372-2381.
|
| [5] |
Pellagatti A,Boultwood J. The molecular pathogenesis of the myelodysplastic syndromes[J]. Eur J Haematol, 2015, 95(1): 3-15.
|
| [6] |
Saumell S,Solé F,Arenillas L, et al. Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?[J]. PLoS One, 2015, 10(6): e0129375.
|
| [7] |
Harada H,Harada Y,Niimi H, et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia[J]. Blood, 2004, 103(6): 2316-2324.
|
| [8] |
Inoue D,Bradley RK,Abdel-Wahab O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis[J]. Genes Dev, 2016, 30(9): 989-1001.
|
| [9] |
Aslan D,Garde C,Nygaard MK, et al. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations[J]. Oncotarget, 2016, 7(9): 9951-9963.
|
| [10] |
Otto T,Sicinski P. Cell cycle proteins as promising targets in cancer therapy[J]. Nat Rev Cancer, 2017, 17(2): 93-115.
|
| [11] |
Kadia TM,Jabbour E,Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes[J]. Semin Oncol, 2011, 38(5): 682-692.
|